Because the ET-1/ETAR axis may activate both tumor suppressive and oncogenic features in cancer cells, ligands that target Gαs/cAMP/PKA signaling could be a promising new treatment option for a variety of cancers. This evidence concerns the gene EDNRA and cancer.